| Gastric Adenocarcinoma

Cyramza vs Trazimera

Side-by-side clinical, coverage, and cost comparison for gastric adenocarcinoma.

Deep comparison between: Cyramza vs Trazimera with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTrazimera has a higher rate of injection site reactions vs Cyramza based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Trazimera but not Cyramza, including UnitedHealthcare

Category

Cyramza

Trazimera

At A Glance

RouteIV infusion

FrequencyEvery 2 weeks

ClassVEGFR2 antagonist

RouteIV infusion

FrequencyWeekly or every 3 weeks

ClassHER2/neu receptor antagonist

Indications

Gastric Adenocarcinoma
Non-Small Cell Lung Carcinoma
Metastasis from malignant neoplasm of colon and/or rectum
Liver carcinoma

Breast Carcinoma
Gastric Adenocarcinoma
Adenocarcinoma of the gastroesophageal junction

Dosing

Gastric Adenocarcinoma 8 mg/kg every 2 weeks by IV infusion as a single agent or in combination with weekly paclitaxel.

Non-Small Cell Lung Carcinoma (EGFR exon 19/21, first-line) 10 mg/kg every 2 weeks by IV infusion in combination with erlotinib.

Non-Small Cell Lung Carcinoma (post-platinum progression) 10 mg/kg by IV infusion on Day 1 of a 21-day cycle in combination with docetaxel.

Metastasis from malignant neoplasm of colon and/or rectum 8 mg/kg every 2 weeks by IV infusion prior to FOLFIRI.

Liver carcinoma 8 mg/kg every 2 weeks by IV infusion as a single agent.

Breast Carcinoma (adjuvant) 4 mg/kg loading dose over 90 min IV, then 2 mg/kg weekly for 12-18 weeks, then 6 mg/kg IV q3w to complete 52 weeks total; alternatively, 8 mg/kg loading dose over 90 min IV, then 6 mg/kg IV q3w for 52 weeks.

Breast Carcinoma (metastatic) 4 mg/kg loading dose over 90 min IV, then 2 mg/kg weekly IV until disease progression.

Gastric Adenocarcinoma, Adenocarcinoma of the gastroesophageal junction 8 mg/kg loading dose over 90 min IV, then 6 mg/kg IV over 30-90 min q3w until disease progression.

Contraindications

—

Drug Interactions

194View drug interactions

1058View drug interactions

Adverse Reactions

Most common (>=10%) Hypertension, fatigue/asthenia, neutropenia, diarrhea, epistaxis, peripheral edema, stomatitis, proteinuria, thrombocytopenia, decreased appetite, nausea.

Serious Febrile neutropenia, pneumonia, hemorrhage, gastrointestinal perforation, arterial thromboembolic events, impaired wound healing, posterior reversible encephalopathy syndrome, proteinuria including nephrotic syndrome, infusion-related reactions, sepsis.

Postmarketing Thrombotic microangiopathy, hemangioma, dysphonia, arterial aneurysms/dissections/rupture, heart failure.

Most common Fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, myalgia

Serious Cardiomyopathy, severe infusion reactions, pulmonary toxicity, embryo-fetal toxicity, exacerbation of chemotherapy-induced neutropenia

Postmarketing Infusion reaction, oligohydramnios or oligohydramnios sequence, glomerulopathy, immune thrombocytopenia, tumor lysis syndrome

Pharmacology

Ramucirumab is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands VEGF-A, VEGF-C, and VEGF-D, inhibiting ligand-stimulated activation of VEGFR2 and thereby inhibiting endothelial cell proliferation, migration, and angiogenesis.

Trastuzumab-qyyp is a HER2/neu receptor antagonist that inhibits proliferation of HER2-overexpressing human tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) preferentially on HER2-overexpressing cancer cells compared with cells that do not overexpress HER2.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Cyramza